Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2023-09-27 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
特一药业集团股份有限公司2023年度以简易程序向特定对象发行股票之上市公告书
Capital/Financing Update Classification · 100% confidence The document is a detailed announcement regarding a 2023 private placement of new shares by 特一药业集团股份有限公司 (Teyi Pharmaceutical Group Co., Ltd.). It includes specifics on the number of shares issued, pricing, subscription details, investor information, regulatory approvals, and related procedures. The content focuses on the issuance and listing of new shares to specific investors, including subscription prices, allotment, and lock-up periods. This matches the description of a Capital/Financing Update, which covers company fundraising and capital structure changes. The document is lengthy (15,000 characters) and contains substantive details about the financing event itself, not merely an announcement of a report or a brief summary. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2023-09-27 Chinese
关于董事、监事、高级管理人员持股情况变动的报告
Director's Dealing Classification · 100% confidence The document is a report about changes in shareholdings of directors, supervisors, and senior management personnel following a specific share issuance. It details the number of shares held before and after the issuance and notes that the shareholding percentages have been diluted due to the increase in total shares. The document is titled as a report on shareholding changes of board members and senior management, which aligns with the definition of Director's Dealing (DIRS) filings, which report personal share transactions by company directors and executives. The document is not an announcement of a report publication, nor is it a full financial report or other types of filings. Therefore, the correct classification is DIRS.
2023-09-27 Chinese
特一药业集团股份有限公司2023年度以简易程序向特定对象发行股票募集资金到位验资报告
Regulatory Filings
2023-09-27 Chinese
东莞证券股份有限公司关于特一药业集团股份有限公司2023年度以简易程序向特定对象发行股票之上市保荐书
Capital/Financing Update Classification · 95% confidence The document is titled as a "上市保荐书" which translates to "Listing Sponsorship Letter" or "Sponsorship Document" related to a specific stock issuance by 特一药业集团股份有限公司 in 2023. It details the issuance of shares via a simplified procedure to specific investors, including financial data, risk factors, issuance details, pricing, allotment, and regulatory compliance. The document is issued by 东莞证券股份有限公司 as the sponsor and underwriter. It contains detailed financial data, issuance terms, regulatory approvals, and compliance statements. This type of document is a formal underwriting and sponsorship report related to a capital raising event, specifically a private placement or targeted share issuance. It is not a general annual report, earnings release, or management discussion. It is a detailed capital/financing update document describing the issuance of new shares, pricing, allotment, and regulatory compliance. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and content confirm it is the full report, not just an announcement or certification.
2023-09-27 Chinese
国浩律师（深圳）事务所关于特一药业集团股份有限公司2023年度以简易程序向特定对象发行股票之发行过程及认购对象合规性的法律意见书
Capital/Financing Update Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding a company's 2023 private placement of shares to specific investors. It details the approval and authorization process, compliance with regulatory requirements, subscription and allocation procedures, investor qualifications, and legal compliance of the issuance process. The document is a standalone legal opinion on a capital raising event, specifically a private placement of shares, and does not contain financial statements or quarterly/annual financial results. It is not an announcement of a report but a substantive legal opinion related to a capital issuance. Therefore, the document fits best under the category of Capital/Financing Update (CAP).
2023-09-27 Chinese
关于公司药品尼群地平片首家通过一致性评价的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the approval of a pharmaceutical product (尼群地平片) passing a consistency evaluation by the national drug regulatory authority. It includes details about the drug, its approval, and the impact on the company. The document is short (1121 characters) and serves as a formal public announcement rather than a detailed financial or regulatory report. It does not contain financial statements, management discussion, or detailed regulatory filings. It is not an earnings release, annual report, or any form of financial report. It is also not a voting result, board change, or capital update. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about product approval and company impact, which does not fit into more specific categories.
2023-09-19 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.